If thats the case, it makes sense about the 42 day

If thats the case, it makes sense about the 42 day mark - that would a) allow people with tissue damage to recover (post covid) vs those (unfortunate ones) on placebo that were not able to recover. 42 day could be a significantly different p value. I hope they are able to show a trend on the 42 day data they have (not all 393) and that it is a strong argument. I hope they are also able to get the 36 day etc by the time the meet with the FDA. It's all going to be about telling a story in that meeting with the data, showing trends about S/C recover on LL etc.